• On Facebook
  • On Twitter
  • On Youtube
  • On Instagram
  • On LinkedIn

BC Centre for Excellence in HIV/AIDS

  • Home
  • News & Multimedia
    • BC-CfE Announcements
    • News
    • News Releases
    • Forecast Newsletter
    • Blog
    • Video
  • Events
    • Current Events
    • Past Events
  • About Us
    • About Us
    • John Ruedy Clinic (JRC)
    • Our Team
    • Committees
  • Careers
  • Media Guide
  • Contact
    • BC-CfE Contacts
    • Media Resources

Search form

Navigation
  • Treatment as Prevention
    • About Us
    • Treatment as Prevention®
    • STOP HIV/AIDS
    • TasP® International Workshop
    • The Hope to Health Research & Innovation Centre
    • Donate
  • Research
    • Epidemiology & Population Health
    • International Program
    • Laboratory Program
    • AIDS Research Program
    • Urban Health Acute Care Unit
  • Healthcare Providers
    • Therapeutic Guidelines
      • About
      • Primary Care
      • Adults
      • Pediatric
      • Management of Acute HIV Infections
      • HIV Post-Exposure Prophylaxis (PEP)
      • HIV Pre-Exposure Prophylaxis (PrEP)
      • Opportunistic Infection
      • Pregnant Women
      • BC Centre for Excellence in HIV/AIDS CDET Committee Statement on the use of COVID-19 mRNA vaccines (Pfizer and Moderna) in Persons living with HIV
      • BC-CfE Guidelines for the use of Paxlovid® and ARVs
      • COVID-19
    • Laboratory Test Order Forms
    • Post-Exposure Prophylaxis (PEP)
    • HIV Pre-Exposure Prophylaxis (PrEP)
    • Drug Treatment Program
    • HIV Drug Safety
    • Healthcare Resources
  • Education & Training
  • Publications
    • Articles & Papers
    • BC-CfE Documents
    • BC-CfE Reports
    • Forecast Newsletter
    • HIV Pulse
  • Blog
  • Treatment as Prevention
    • About Us
    • Treatment as Prevention®
    • STOP HIV/AIDS
    • TasP® International Workshop
    • The Hope to Health Research & Innovation Centre
    • Donate
  • Research
    • Epidemiology & Population Health
    • International Program
    • Laboratory Program
    • AIDS Research Program
    • Urban Health Acute Care Unit
  • Healthcare Providers
    • Therapeutic Guidelines
      • About
      • Primary Care
      • Adults
      • Pediatric
      • Management of Acute HIV Infections
      • HIV Post-Exposure Prophylaxis (PEP)
      • HIV Pre-Exposure Prophylaxis (PrEP)
      • Opportunistic Infection
      • Pregnant Women
      • BC Centre for Excellence in HIV/AIDS CDET Committee Statement on the use of COVID-19 mRNA vaccines (Pfizer and Moderna) in Persons living with HIV
      • BC-CfE Guidelines for the use of Paxlovid® and ARVs
      • COVID-19
    • Laboratory Test Order Forms
    • Post-Exposure Prophylaxis (PEP)
    • HIV Pre-Exposure Prophylaxis (PrEP)
    • Drug Treatment Program
    • HIV Drug Safety
    • Healthcare Resources
  • Education & Training
  • Publications
    • Articles & Papers
    • BC-CfE Documents
    • BC-CfE Reports
    • Forecast Newsletter
    • HIV Pulse
  • Blog
  • BC-CfE Guidelines for the use of Paxlovid® and ARVs
  • BC-CfE CDET Statement on the use of COVID-19 vaccines in Persons Living with HIV

BC-CFE GUIDELINES FOR THE USE OF PAXLOVID® AND ARVS

Safety considerations for nirmatrelvir/ritonavir (Paxlovid®) use in persons living with HIV whether or not on antiretroviral treatment, or persons at risk of HIV while on PrEP who are diagnosed with COVID-19 infection

The COVID-19 therapy Paxlovid® consists of the antiviral medication nirmatrelvir co-packaged with the pharmacokinetic enhancer (“booster”) ritonavir, taken as a twice daily, oral, five-day treatment course, with dosage adjustment required for renal impairment (see prescribing information).

Nirmatrelvir/ritonavir treatment is initiated as soon as possible following a positive SARS-CoV-2 test result. Eligibility criteria for nirmatrelvir/ritonavir vary between Canadian provinces and will likely evolve over time. Also, eligibility in British Columbia may be expanded as drug supply increases. Therefore, prescribers are strongly encouraged to refer to current nirmatrelvir/ritonavir prescribing information and local guidelines for treatment eligibility and general contraindications/precautions. In British Columbia, see the BC Centre for Disease Control website: http://www.bccdc.ca/health-professionals/clinical-resources/covid-19-care/clinical-care/treatments

Download: BC-CfE Guidelines for the use of Paxlovid® and ARVs

BC-CFE CDET STATEMENT ON THE USE OF COVID-19 VACCINES IN PERSONS LIVING WITH HIV

People living with HIV (PLWH) aged 5 years or older should be fully vaccinated for COVID-19, regardless of CD4 count provided that they do not have contraindications to the available age-appropriate vaccines (see below). Although the evidence was mixed in earlier studies, more recently, multiple large studies have indicated that PLWH are at increased risk of serious illness and death due to COVID-19. To date, there appears to be no significant difference in the safety profile of the authorized COVID-19 vaccines in PLWH compared to the general population.

Read More

In this section

  • Therapeutic Guidelines
    • About
    • COVID-19
    • Primary Care
    • Adults
    • Pediatric
    • Management of Acute HIV Infections
    • HIV Post-Exposure Prophylaxis (PEP)
    • Pre-Exposure Prophylaxis (PrEP)
    • Opportunistic Infection
    • Pregnant Women
    • Provincial Best Practice in HIV Case Management
  • Committee
  • Support Services Contact

  • For Healthcare Providers

  • Therapeutic Guidelines
    Up-to-date HIV treatment info
  • Laboratory Test Order Forms
    Current versions of order requisitions
  • Post-Exposure Prophylaxis (PEP)
  • Pre-Exposure Prophylaxis (PrEP)
  • Drug Treatment Program
    Information on anti-HIV medications
  • HIV Drug Safety
    Safety Alerts
    Report Adverse Drug Reactions
  • Healthcare Resources
    Resources of particular interest to Healthcare Professionals
  • On Facebook
  • On Twitter
  • On Youtube
  • On Instagram
  • On LinkedIn

Search form

  • Home
  • Contact
  • Webmail
  • BC-CfE's Privacy Notice
  • Subscribe to our mailing lists
  • Home
  • About Us
  • Careers
  • News & Multimedia
  • Events
  • Webmail
  • Media Guide
  • Contact
  • BC-CfE's Privacy Notice

Our work serves clients and communities across British Columbia on lands and waters cared for and nurtured by the many distinct First Nations across the province. The BC-CfE humbly and gratefully acknowledge the stewards of these lands, particularly the xʷməθkʷəy̓əm (Musqueam), Sḵwx̱wú7mesh (Squamish), and səl̓ílwətaʔ (Tsleil-Waututh) on whose unceded, traditional and ancestral territories our offices are located.

© Copyright BC Centre for Excellence in HIV/AIDS
St. Paul's Hospital 608–1081 Burrard Street, Vancouver, BC, Canada V6Z 1Y6
Tel: 604-806-8477 | Fax: 604-806-9044
General inquiries: info@bccfe.ca
Media inquiries: communications@bccfe.ca
(Please do not use any of these email addresses to send personal information or book an appointment. To book appointments or contact the H2H clinic, please call 604-416-1517 or fax: 604-564-4893. Do not send your or your client's personal information via email.)

© Copyright BC Centre for Excellence in HIV/AIDS
St. Paul's Hospital 608–1081 Burrard Street, Vancouver, BC, Canada V6Z 1Y6
Tel: 604-806-8477 | Fax: 604-806-9044
General inquiries: info@bccfe.ca
Media inquiries: communications@bccfe.ca
(Please do not use any of these email addresses to send personal information or book an appointment. To book appointments or contact the H2H clinic, please call 604-416-1517 or fax: 604-564-4893. Do not send your or your client's personal information via email.)

Our work serves clients and communities across British Columbia on lands and waters cared for and nurtured by the many distinct First Nations across the province. The BC-CfE humbly and gratefully acknowledge the stewards of these lands, particularly the xʷməθkʷəy̓əm (Musqueam), Sḵwx̱wú7mesh (Squamish), and səl̓ílwətaʔ (Tsleil-Waututh) on whose unceded, traditional and ancestral territories our offices are located.

Providence Health Care